CA-WILSHIRE/XTP
29.8.2024 15:01:32 CEST | Business Wire | Press release
Wilshire Advisors LLC (“Wilshire”), a leading global financial services firm, today announced that it has joined forces with XTP Implementation Services (“XTP”), a tech-enabled and data-driven specialist focused on improving transparency, reducing risk, enhancing investment governance, and increasing net returns for institutional investors globally. Through this partnership, which was effectuated by an acquisition of XTP by Wilshire, with simultaneous reinvestment in Wilshire by former XTP shareholders, XTP will continue to operate independently under its existing leadership team and brand. Financial terms of the transaction were not disclosed.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240828886722/en/
XTP is a market leader in cost transparency analytics, with a 20-year history of serving public and private investors, including pension funds, insurance companies, sovereign wealth funds, investment consultants, outsourced chief investment officers, endowments and foundations, and family offices. With more than $3 trillion in assets analyzed across 10,000 portfolios in North America and Europe, XTP helps its clients reduce investment-related costs and risks while enhancing governance. Combining deep industry experience and proprietary software, benchmarking databases, and forensic capabilities allows XTP to identify optimization potential across the investment value chain of public and private market portfolios. XTP clients benefit from a risk-free increase in net returns.
Andy Stewart, CEO at Wilshire, said: “We are excited to partner with XTP and bring its cost and risk-reduction services to our institutional clients, which will benefit from the power of its sophisticated insights and solutions. Throughout our discussions, it was clear that Wilshire and XTP share a holistic, client-centric approach that seeks to align our success with that of our clients. On behalf of Wilshire, I extend a warm welcome to the talented XTP team and look forward to collaborating for the benefit of our combined client base.”
Philipp Henrich, Founder and CEO at XTP, said: “We welcome our partnership with Wilshire, whose solutions, clients, and geographic footprint are complementary to ours. By joining forces, we have the opportunity to leverage the resources of a global service provider with a very strong presence in North America. This will enable us to offer our capabilities to an expanded client base while continuing to provide our valued, long-standing customers personalized, mission-critical support. We could not be more optimistic about this new, bright chapter for XTP with Wilshire alongside us.”
Jason Schwarz, President and Deputy CEO at Wilshire, said: “Institutional investors worldwide are more focused than ever on efficiency and transparency, seeking to better understand, disclose, and manage the true costs of their investments. XTP has an impressive 20-year track record and unmatched ability to identify cost and risk-reduction opportunities and translate those insights into enhanced returns. By bringing together XTP’s proprietary capabilities and Wilshire’s multifaceted platform, we will be even better positioned to empower clients with solutions that address their top concerns and deliver even more value.”
Solomon Partners and Kirkland & Ellis LLP served as financial advisor and legal advisor to Wilshire, respectively. XTP shareholders were advised by DLA Piper.
About Wilshire
Wilshire is a leading global financial services firm and trusted partner to approximately 500 leading institutional investors and financial intermediaries. Our clients rely on us to improve investment outcomes for a better future. Wilshire advises on over $1.4 trillion in assets and manages over $121 billion in assets as of March 31, 2024. Wilshire is headquartered in the United States with offices worldwide. More information on Wilshire can be found at www.wilshire.com.
About XTP
XTP is a specialist consultant focusing on transparency, cost, and risk. XTP actively supports large institutional asset owners globally in turning data into measurable results. By creating full cost transparency in public and private market portfolios XTP assures contract compliance, eliminates process inefficiencies and operation risks, and optimizes costs without changing the existing investment set-up. More information on XTP can be found at www.xtp-group.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240828886722/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release
Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom